Methods: Based on MAPI® database collecting price cuts and ASMR ratings, we screened medicines granted relevant ASMRs, and identify those affected by at least one price cut within the 5-years period following their admission to reimbursement. Results: As of June 11, 2015, amongst medicines with price cuts despite an ASMR I to III or IV granted in less than 5 years, 12 had been admitted to reimbursement for more than 5 years, recent ASMR being granted to extended indications. Within the 5 years following their reimbursement, price cuts were observed for only 4 medicines granted an ASMR III (abiraterone, boceprevir, telaprevir and vemurafenib) and 4 granted an ASMR IV (apixaban, denosumab, solifenacin and ulipristal acetate). ConClusions: Overall, the 5-years price stability for innovative medicines fulfilling the criteria set by the agreement is verified, price cuts concerning mainly mature products. Price cuts for qualified medicines within the first 5 years may be due to changes in prices in reference countries, budget impact concerns or other reasons kept confidential.

A23the theoretical framework to guide the focus group discussions. Each session was audio-recorded, transcribed, and participant responses were analyzed for qualitative content. Results: Two, 60 minute focus groups (Total N= 12) were conducted. Time constraints and privacy issues presented as major themes in the discussions. Regarding advantages/disadvantages, participants emphasized the importance of counseling for the discussion of potential drug interactions and side effects of their medications and felt that their doctor would approve of them speaking with a pharmacist about their medications. However, both patient and pharmacist' time constraints presented as a barrier to counseling. The majority of participants also stated that they would receive counseling more readily if it were provided in a more private environment. Only one participant was aware of MTM services and medication counseling requirements by law, however the majority stated that if they were aware of this mandate they would more readily accept pharmacist provided counseling. ConClusions: The identification of barriers to pharmacist provided counseling, specifically privacy and time limitations, may be beneficial for creating specific interventions that would increase patients' intentions to receive pharmacist provided counseling.

ConClusions: Understanding the economic burden of dying helps promote better and cost-effective ways of promoting palliative care, old and readmitted deaths are less costly. HealtH Care Use & PoliCy stUdies -regulation of Health Care sector PHP56 From "GeneriC sCHeme" to "Brand-GeneriC sCHeme": tHe eFFeCt oF new PoliCy (2003-2004) on eFFiCienCy oF iranian PHarmaCeUtiCal indUstry

No abstract

websites, data on file and miscellaneous. The Journal articles were browsed in PubMed and Google. All collected full length articles and abstracts were examined for key worlds Pharmacoeconomic, Cost effectiveness, Cost utility, Cost minimization, Cost benefit and quality of life by two independent reviewers. Descriptive statistics was used for reporting the results. RESULTS: All 14 journals searched contained 1435 advertisements of 237 brands. The total references quoted in these advertisements were found to be 242. Of these 242 references 57.43% were from articles published in journals, 25.2% from miscellaneous sources and 11.15 % from data on file. Only 4 (0.2%) references among the published research articles were having pharmacoeconomics and humanistic outcomes research evidence. CONCLUSIONS: The present study clearly indicates the negligible number of pharmacoeconomics and humanistic outcomes research evidence used in advertisements published in scientific journals and there is a further need to extend this study for other mode of advertisements such as detailing aids, leave behind literature and official websites of pharmaceutical companies.